Oncology Institute (NASDAQ:STLN) Stock Sold by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $15,001 and $50,000 in Oncology Institute stock on September 18th.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Stock Down 6.3%

STLN stock opened at $6.29 on Tuesday. The firm’s 50 day simple moving average is $6.46. Oncology Institute, Inc. has a 52-week low of $2.32 and a 52-week high of $7.13. The stock has a market capitalization of $621.70 million, a price-to-earnings ratio of -20.97 and a beta of 0.39.

Oncology Institute (NASDAQ:STLN) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) EPS for the quarter. The company had revenue of $161.28 million for the quarter, compared to the consensus estimate of $152.80 million. Analysts forecast that Oncology Institute, Inc. will post -0.21 earnings per share for the current year.

Institutional Trading of Oncology Institute

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new stake in shares of Oncology Institute in the second quarter worth about $961,000. State Street Corp purchased a new position in Oncology Institute during the second quarter worth $8,432,000. Bank of America Corp DE bought a new stake in shares of Oncology Institute in the 2nd quarter worth about $2,129,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Oncology Institute by 169.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock valued at $1,288,000 after buying an additional 263,699 shares during the period. Finally, Cetera Investment Advisers boosted its holdings in Oncology Institute by 427.8% during the 1st quarter. Cetera Investment Advisers now owns 128,195 shares of the company’s stock valued at $394,000 after acquiring an additional 103,908 shares during the period. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Insider Transactions at Oncology Institute

In related news, major shareholder Jorey Chernett bought 12,000 shares of Oncology Institute stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $6.54 per share, with a total value of $78,480.00. Following the completion of the transaction, the insider owned 10,660,858 shares in the company, valued at $69,722,011.32. The trade was a 0.11% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the transaction, the director owned 411,976 shares in the company, valued at $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on STLN shares. Weiss Ratings assumed coverage on shares of Oncology Institute in a research note on Thursday, August 6th. They set a “sell (d-)” rating on the stock. Lake Street Capital assumed coverage on shares of Oncology Institute in a research note on Monday, July 6th. They issued a “buy” rating and a $10.00 price target for the company. Needham & Company LLC boosted their price objective on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, BTIG Research increased their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Oncology Institute presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

About Oncology Institute

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.